Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dream control therapy eases night terrors and sleep paralysis in narcolepsy patients

NCT ID NCT07609537

Symptom relief Sponsor: Institute of Behavioral Sleep Medicine, Colombia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a six-session behavioral therapy that teaches people with narcolepsy type 1 how to become aware during dreams (lucid dreaming) and control frightening images. Ninety-eight adults took part, with half receiving the therapy and half getting standard care. The goal was to reduce the frequency and distress of hypnagogic hallucinations and sleep paralysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cognitive behavioral therapy with lucid dreaming training
What this could lead to
If it works, this could offer a drug-free way to ease frightening hallucinations and sleep paralysis in people with narcolepsy.
What could go wrong
This is a small, completed trial with 98 participants, so results may not apply to everyone. The therapy requires time and effort, and not everyone can learn lucid dreaming.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

98 people

The number who actually took part.

Started

Mar 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years diagnosed with Narcolepsy Type 1, confirmed by clinical evaluation and polysomnography. * Experiencing clinically significant hypnagogic hallucinations and/or sleep paralysis. * Stable pharmacological treatment for narcolepsy, such as modafinil and/or methylphenidate. * Able and willing to provide informed consent electronically. * Available to participate in six weekly virtual intervention sessions. * Willing to adhere to structured medical follow-up, including sleep hygiene education, nap guidance, sleep habit stabilization, and participation in sleep schedule programs. Exclusion Criteria: * Presence of severe psychiatric disorders or dissociative disorders. Active use of psychoactive substances during the study period. * Participation in other interventions targeting lucid dreaming or imagery rehearsal during the trial. * Any medical or cognitive condition that, in the investigator's judgment, would interfere with participation or adherence to the intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central disorders of hypersomnolence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence Hallucinations hypersomnia narcolepsy narcolepsy without cataplexy narcolepsy-cataplexy syndrome Sleep Paralysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central disorders of hypersomnolence Hypnagogic hallucinations Narcolepsy type 1 Rem sleep intrusion symptoms Sleep paralysis

Contacts and locations

Locations

  • Bahavioral Sleep Medicine Institute

    Medellín, Antioquia, 050021, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.